Cargando…
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
Tofacitinib is a Janus kinase 1–3 inhibitor initially approved for the treatment of rheumatoid arthritis and now approved for the treatment of moderately to severely active ulcerative colitis (UC). We present the case of a patient with UC and seronegative inflammatory arthritis in whom arthritis pro...
Autores principales: | Wang, Wenfei, Cleveland, Noa Krugliak, Ollech, Jacob, Rubin, David T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831149/ https://www.ncbi.nlm.nih.gov/pubmed/31750389 http://dx.doi.org/10.14309/crj.0000000000000226 |
Ejemplares similares
-
Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021) -
A Summary of the BRIDGe Summit on Damage-Related Progression of Ulcerative Colitis: Establishing Research Priorities
por: Cleveland, Noa Krugliak, et al.
Publicado: (2022) -
Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020) -
Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021) -
Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)